BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 25832685)

  • 1. Long-term quality of life after swallowing and salivary-sparing chemo-intensity modulated radiation therapy in survivors of human papillomavirus-related oropharyngeal cancer.
    Vainshtein JM; Moon DH; Feng FY; Chepeha DB; Eisbruch A; Stenmark MH
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):925-33. PubMed ID: 25832685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicities affecting quality of life after chemo-IMRT of oropharyngeal cancer: prospective study of patient-reported, observer-rated, and objective outcomes.
    Hunter KU; Schipper M; Feng FY; Lyden T; Haxer M; Murdoch-Kinch CA; Cornwall B; Lee CS; Chepeha DB; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):935-40. PubMed ID: 23040224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemo-IMRT of oropharyngeal cancer aiming to reduce dysphagia: swallowing organs late complication probabilities and dosimetric correlates.
    Eisbruch A; Kim HM; Feng FY; Lyden TH; Haxer MJ; Feng M; Worden FP; Bradford CR; Prince ME; Moyer JS; Wolf GT; Chepeha DB; Ten Haken RK
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):e93-9. PubMed ID: 21592678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reducing xerostomia after chemo-IMRT for head-and-neck cancer: beyond sparing the parotid glands.
    Little M; Schipper M; Feng FY; Vineberg K; Cornwall C; Murdoch-Kinch CA; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):1007-14. PubMed ID: 22056067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported voice and speech outcomes after whole-neck intensity modulated radiation therapy and chemotherapy for oropharyngeal cancer: prospective longitudinal study.
    Vainshtein JM; Griffith KA; Feng FY; Vineberg KA; Chepeha DB; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2014 Aug; 89(5):973-980. PubMed ID: 24803039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of Dysgeusia in Patients With Oropharyngeal Cancer Treated With Chemotherapy and Intensity Modulated Radiation Therapy.
    Sapir E; Tao Y; Feng F; Samuels S; El Naqa I; Murdoch-Kinch CA; Feng M; Schipper M; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2016 Oct; 96(2):354-361. PubMed ID: 27473816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results.
    Feng FY; Kim HM; Lyden TH; Haxer MJ; Worden FP; Feng M; Moyer JS; Prince ME; Carey TE; Wolf GT; Bradford CR; Chepeha DB; Eisbruch A
    J Clin Oncol; 2010 Jun; 28(16):2732-8. PubMed ID: 20421546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of submandibular gland and swallowing structure sparing to post-radiation therapy PEG dependence in oropharynx cancer patients treated with split-neck IMRT technique.
    Gensheimer MF; Nyflot M; Laramore GE; Liao JJ; Parvathaneni U
    Radiat Oncol; 2016 Nov; 11(1):151. PubMed ID: 27846899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer: initial report.
    Jabbari S; Kim HM; Feng M; Lin A; Tsien C; Elshaikh M; Terrel JE; Murdoch-Kinch C; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):725-31. PubMed ID: 16199308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sparing bilateral neck level IB in oropharyngeal carcinoma and xerostomia outcomes.
    Tam M; Riaz N; Kannarunimit D; Peña AP; Schupak KD; Gelblum DY; Wolden SL; Rao S; Lee NY
    Am J Clin Oncol; 2015 Aug; 38(4):343-7. PubMed ID: 26208401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures.
    Feng FY; Kim HM; Lyden TH; Haxer MJ; Feng M; Worden FP; Chepeha DB; Eisbruch A
    Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1289-98. PubMed ID: 17560051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-volume toxicity modeling for de-intensified chemo-radiation therapy for HPV-positive oropharynx cancer.
    Mavroidis P; Price A; Fried D; Kostich M; Amdur R; Mendenhall W; Liu C; Das S; Marks LB; Chera B
    Radiother Oncol; 2017 Aug; 124(2):240-247. PubMed ID: 28712533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sparing all salivary glands with IMRT for head and neck cancer: Longitudinal study of patient-reported xerostomia and head-and-neck quality of life.
    Hawkins PG; Lee JY; Mao Y; Li P; Green M; Worden FP; Swiecicki PL; Mierzwa ML; Spector ME; Schipper MJ; Eisbruch A
    Radiother Oncol; 2018 Jan; 126(1):68-74. PubMed ID: 28823405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of long term (10-years+) dysphagia and trismus in patients treated with concurrent chemo-radiotherapy for advanced head and neck cancer.
    Kraaijenga SA; Oskam IM; van der Molen L; Hamming-Vrieze O; Hilgers FJ; van den Brekel MW
    Oral Oncol; 2015 Aug; 51(8):787-94. PubMed ID: 26027851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sparing the larynx and esophageal inlet expedites feeding tube removal in patients with stage III-IV oropharyngeal squamous cell carcinoma treated with intensity-modulated radiotherapy.
    Amin N; Reddy K; Westerly D; Raben D; DeWitt P; Chen C
    Laryngoscope; 2012 Dec; 122(12):2736-42. PubMed ID: 22991101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosimetric Predictors of Patient-Reported Xerostomia and Dysphagia With Deintensified Chemoradiation Therapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma.
    Chera BS; Fried D; Price A; Amdur RJ; Mendenhall W; Lu C; Das S; Sheets N; Marks L; Mavroidis P
    Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1022-1027. PubMed ID: 28721884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparisons of dysphagia and quality of life (QOL) in comparable patients with HPV-positive oropharyngeal cancer receiving chemo-irradiation or cetuximab-irradiation.
    Samuels SE; Tao Y; Lyden T; Haxer M; Spector M; Malloy KM; Prince ME; Bradford CR; Worden FP; Schipper M; Eisbruch A
    Oral Oncol; 2016 Mar; 54():68-74. PubMed ID: 26776757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of life among long-term survivors of head and neck cancer treated by intensity-modulated radiotherapy.
    Chen AM; Daly ME; Farwell DG; Vazquez E; Courquin J; Lau DH; Purdy JA
    JAMA Otolaryngol Head Neck Surg; 2014 Feb; 140(2):129-33. PubMed ID: 24337483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preservation of oral health-related quality of life and salivary flow rates after inverse-planned intensity- modulated radiotherapy (IMRT) for head-and-neck cancer.
    Parliament MB; Scrimger RA; Anderson SG; Kurien EC; Thompson HK; Field GC; Hanson J
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):663-73. PubMed ID: 14967418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can IMRT or brachytherapy reduce dysphagia associated with chemoradiotherapy of head and neck cancer? The Michigan and Rotterdam experiences.
    Eisbruch A; Levendag PC; Feng FY; Teguh D; Lyden T; Schmitz PI; Haxer M; Noever I; Chepeha DB; Heijmen BJ
    Int J Radiat Oncol Biol Phys; 2007; 69(2 Suppl):S40-2. PubMed ID: 17848291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.